CGEN
Compugen Ltd. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website cgen.com
- Employees(FY) 69
- ISIN IL0010852080
Performance
+0.96%
1W
+3.94%
1M
-12.08%
3M
+244.6%
6M
+6.57%
YTD
+174.35%
1Y
Profile
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Technical Analysis of CGEN 2024-05-10
Overview:
In analyzing the technical indicators for CGEN over the last 5 days, we will delve into the trends, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for potential inves...
Recent News & Updates
- 2023-11-05 18:00
- 2023-11-03 04:35
- 2023-10-30 21:00
- 2023-10-23 19:00
- 2023-10-02 19:00
- 2023-10-01 19:00
- 2023-09-26 21:00
- 2023-09-13 21:40
- 2023-08-30 19:00
- 2023-08-28 21:40
Has Compugen (CGEN) Outpaced Other Medical Stocks This Year?(Yahoo Finance)
- 2023-08-10 00:13
Compugen Ltd. (NASDAQ:CGEN) Q2 2023 Earnings Call Transcript(Yahoo Finance)
- 2023-08-06 19:17
Compugen: Q2 Earnings Snapshot(Yahoo Finance)
- 2023-08-06 19:00
Compugen Reports Second Quarter 2023 Results(Yahoo Finance)
- 2023-07-23 19:00
- 2023-07-16 19:00
- 2023-06-21 19:00
- 2023-06-12 19:00
- 2023-06-04 19:00
- 2023-06-01 19:09
- 2023-05-24 22:49
Cathie Wood is Selling These 12 Stocks in 2023(Yahoo Finance)
- 2023-05-17 21:40
- 2023-05-14 19:10
Compugen: Q1 Earnings Snapshot(Yahoo Finance)
- 2023-05-14 19:00
Compugen Reports First Quarter 2023 Results(Yahoo Finance)
- 2023-05-10 19:00
- 2023-05-08 19:00
- 2023-04-30 19:00
- 2023-04-26 19:00
- 2023-04-25 19:00
- 2023-03-14 19:00
- 2023-03-13 21:40